What CLL Society does

CLL Society is a 501(c)(3) nonprofit organization founded in 2013 by Dr. Brian Koffman, a physician and CLL patient, and Patricia Koffman, a care partner. Headquartered in Nashville, Tennessee and operating with an 11–50 employee team, the organization provides free education, support, advocacy, and research programs for individuals affected by chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). It does not develop commercial technology products; instead it curates physician-reviewed educational content, maintains clinical trial listings, and operates the CLL Medicine Cabinet — a drug information resource covering CLL/SLL therapeutics — alongside a Policy Institute for the immunocompromised community.

The organization's core service offerings include Expert Access™, a free virtual second opinion program delivered through partner Alight's HIPAA-compliant platform connecting US-based patients with world-renowned CLL experts; a Peer Support Program pairing patients one-on-one; CLL-specific support groups; the CareCast podcast; on-demand webinars; the Emotional & Spiritual Advocate Program; the Trusted Care Exchange connecting patients with healthcare providers; and the COVID-19 Resources program for immunocompromised patients. In 2026 the organization launched the CLL Treatment Decision Tool, built with Decera Clinical Education to translate input from five CLL experts into a patient-facing decision aid. The Research Grant Program, launched in 2022 and funded entirely through individual contributions, has cumulatively directed over $2,150,000 to CLL/SLL researchers through Clinical Scholar and Young Investigator Awards.

CLL Society is funded through individual donations and corporate grants/sponsorships from pharmaceutical companies organized into an Industry Advisory Council. The 2026 Council includes Platinum members AbbVie, BeiGene/BeOne, Genentech, and Lilly, and Gold members AstraZeneca and Invivyd. The organization maintains stated editorial independence from corporate donors, does not endorse specific medications, and operates free of charge to patients and caregivers. It has been recognized with a 4-star Charity Navigator rating and a Candid (GuideStar) Platinum Seal of Transparency.

Name

CLL Society

Legal name

CLL Society Inc.

Website

https://cllsociety.org

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

11–50 employees

Short description

CLL Society is a 501(c)(3) nonprofit founded in 2013 that provides free education, support, advocacy, and research funding for patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) and their caregivers. Programs include Expert Access virtual second opinions, peer support, treatment decision tools, and a research grant program funded by individual donations and pharmaceutical sponsorships.

Ownership category

akta.pro rank

Headquarters

HQ city

Chula Vista

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Others

Revenue model

1. Individual Donations: CLL Society is funded primarily through individual donations from patients, caregivers, and supporters of the CLL community. Donations support the organization's mission of education, advocacy, support, and research.
2. Corporate Grants and Sponsorships: CLL Society receives financial support from pharmaceutical and healthcare companies in the form of restricted and unrestricted grants and sponsorships. The organization maintains full editorial independence and does not endorse specific medications or treatments. Corporate partners include AbbVie, BeiGene/BeOne, Genentech, Lilly, AstraZeneca, and Invivyd through the Industry Advisory Council.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels8 records

Core offering

CLL Society is a 501(c)(3) nonprofit that provides free education, support, advocacy, and research programs for patients affected by chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Its core offerings include free virtual expert second opinions (Expert Access™), one-on-one peer support, CLL-specific support groups, physician-curated educational content (CareCast Podcast, Education On-Demand webinars, Medicine Cabinet, Patient Education Toolkit), an interactive CLL Treatment Decision Tool, advocacy through its Policy Institute, and a Research Grant Program funding CLL/SLL investigators.

Product overview

CLL Society is a nonprofit patient-centric, physician-curated organization providing comprehensive education, support, and research for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) patients. The organization offers a suite of patient support services including Expert Access™ (free virtual second opinions), Peer Support Program, Emotional & Spiritual Advocate Program, and CLL-specific support groups. Educational offerings include the CLL Medicine Cabinet (drug information), CLL/SLL Patient Education Toolkit, CareCast Podcast, and Education On-Demand webinars. The CLL Treatment Decision Tool provides algorithmic treatment recommendations based on expert input. CLL Society also funds research through its Research Grant Program and maintains clinical trial information resources.

Differentiator

Problem solved

Functional benefit

Brands

• Expert Access™: A free virtual second opinion program connecting CLL patients with world-renowned CLL experts.
• CareCast Podcast
• Trusted Care Exchange
• Peer Support Program

Products and services

• Expert Access™ Free virtual second opinion consultation service connecting CLL/SLL patients in the United States with world-renowned CLL experts via HIPAA-compliant video consultations, producing expert opinions patients can share with their local treatment team.
• Peer Support Program One-on-one peer support program pairing CLL patients with trained fellow patients for emotional support and shared lived experience.
• Emotional & Spiritual Advocate Program Program supporting the emotional, spiritual, and mental well-being of CLL patients and their care partners.
• Support Groups CLL-specific patient support groups providing community connection and peer support for patients and caregivers.
• CareCast Podcast Educational podcast series providing information and updates on CLL/SLL research, treatments, and patient experiences.
• Education On-Demand On-demand educational activities and webinars for CLL patients covering treatments, research, and disease management.
• CLL Medicine Cabinet Comprehensive resource providing detailed information on CLL medications including dosing, side effects, administration, and management guidance.
• CLL Treatment Decision Tool Interactive treatment decision resource, built with Decera Clinical Education, offering personalized treatment options based on algorithmic inputs from five CLL experts through a patient-completed questionnaire.
• Research Grant Program Research grant program funding novel projects aimed at improving outcomes and quality of life for CLL/SLL patients, having dedicated $2,150,000 to CLL/SLL researchers since 2022.
• CLL/SLL Patient Education Toolkit Comprehensive educational resource covering CLL/SLL basics, testing, staging, treatment options, MRD testing, complications, and disease management tools.
• Trusted Care Exchange Resource connecting CLL patients with healthcare providers and facilitating care coordination.
• COVID-19 Resources COVID-19 information and resources specific to CLL/SLL patients, including action plans, prevention, treatment guidance, and virtual community meetings.

Named customers4 records

Segments3 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Eight partnerships are on record, tiered core and minor.

• AlightcoreStrategic or Co-development PartnerCLL Society partners with Alight, an online second opinion service that uses live video technology to connect patients with top US-based medical specialists. Alight provides HIPAA-compliant platform infrastructure for the Expert Access program's virtual consultations. Eighty percent of those provided a 2nd opinion through Alight were seeking oncology consultations.
• Decera Clinical EducationcoreStrategic or Co-development PartnerCLL Society collaborated with Decera Clinical Education to create the CLL Treatment Decision Tool, offering information about common treatment options for CLL. Decera's mission is to improve clinical care and patient health outcomes through evidence-based educational activities.
• AbbVie (Platinum Industry Advisory Council)minorGTM or Marketing PartnerPlatinum member of CLL Society's 2026 Industry Advisory Council. AbbVie manufactures Imbruvica (ibrutinib) and venetoclax (Venclexta) used in CLL treatment.
• BeiGene/BeOne (Platinum Industry Advisory Council)minorGTM or Marketing PartnerPlatinum member of CLL Society's 2026 Industry Advisory Council. BeiGene manufactures zanubrutinib (Brukinsa) and sonrotoclax (Beqalzi) used in CLL treatment.
• Genentech (Platinum Industry Advisory Council)minorGTM or Marketing PartnerPlatinum member of CLL Society's 2026 Industry Advisory Council. Genentech manufactures obinutuzumab (Gazyva) used in CLL treatment.
• Lilly (Platinum Industry Advisory Council)minorGTM or Marketing PartnerPlatinum member of CLL Society's 2026 Industry Advisory Council.
• AstraZeneca (Gold Industry Advisory Council)minorGTM or Marketing PartnerGold member of CLL Society's 2026 Industry Advisory Council. AstraZeneca manufactures acalabrutinib (Calquence) used in CLL treatment.
• Invivyd (Gold Industry Advisory Council)minorGTM or Marketing PartnerGold member of CLL Society's 2026 Industry Advisory Council. Invivyd focuses on antibody therapeutics for infectious diseases.

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Cancer Support Community: Cancer Support Community provides free psychosocial support, education, and navigation services to cancer patients across all diagnoses. Comparable as a peer cancer-focused patient support nonprofit, though its scope is much broader than CLL/SLL and it lacks CLL-specific medical depth.
• American Cancer Society: American Cancer Society is the largest US cancer-focused nonprofit, providing patient support, research funding, and advocacy across all cancer types. Comparable as a broad peer in cancer patient support and advocacy, though CLL/SLL represents only a tiny fraction of its program focus.
• The Leukemia & Lymphoma Society (LLS): LLS is the largest US nonprofit dedicated to blood cancers including leukemia, lymphoma, myeloma, and myelodysplastic syndromes. Directly comparable as a peer disease-advocacy, research-funding, and patient-support organization, though it operates at much greater scale and across all blood cancers rather than CLL/SLL specifically.

Direct peers

• Patient Advocate Foundation: Patient Advocate Foundation provides case management, financial aid, and access support to patients with chronic and life-threatening illnesses including cancer. Comparable as a peer patient advocacy nonprofit that provides direct service navigation, though it serves all diagnoses rather than focusing on CLL/SLL.
• CLL Global Research Foundation: CLL Global Research Foundation is dedicated exclusively to CLL research funding and global collaboration among CLL investigators. Directly comparable as a CLL-focused nonprofit, though its emphasis is more heavily weighted toward scientific research grants versus patient education and support services.
• Lymphoma Research Foundation: Lymphoma Research Foundation funds lymphoma-specific research and provides patient education and support, including for SLL. Highly comparable mission, funding model (pharma grants plus individual donations), and program portfolio, though it covers all lymphoma subtypes rather than focusing exclusively on CLL/SLL.
• HealthTree Foundation for Multiple Myeloma: HealthTree Foundation runs a comparable disease-specific nonprofit model for multiple myeloma, with free patient education, peer support, specialist directories, and a clinical trial finder. Operates with a similar digital-first, physician-curated approach and pharma funding base, making it a strong functional peer in adjacent hematologic cancer.
• International Waldenstrom's Macroglobulinemia Foundation (IWMF): IWMF is a disease-specific patient nonprofit for Waldenstrom macroglobulinemia, a rare B-cell lymphoma closely related to CLL/SLL. Strong functional peer given shared model of patient education, support groups, expert directories, and research funding for a rare hematologic malignancy.

Others

• National Comprehensive Cancer Network (NCCN): NCCN is an alliance of leading cancer centers that publishes the authoritative clinical practice guidelines used by oncologists treating CLL/SLL. Comparable as an adjacent ecosystem stakeholder that shapes the treatment landscape CLL Society educates patients about, though NCCN is provider-facing rather than patient-facing.

Emerging players

• CLL Research Consortium (CRC): CRC is a multi-institutional research collaboration focused specifically on CLL scientific investigation. Comparable as a CLL-focused research entity, though it operates primarily as a scientific consortium rather than a patient-facing nonprofit with support services.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/cllsociety
• Facebookfacebook.com/CLLsociety
• LinkedInlinkedin.com/company/cll-society

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CLL Society